2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Breast
1
Conditions
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
3
Lung Neoplasms
3
Esophageal Neoplasms
3
Neoplasm Metastasis
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Nonsquamous Non-small Cell Lung Cancer
1
Non-Small Cell Lung Cancer Metastatic
1
Meningeal Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Breast Cancer Metastatic
1
Interventions
Temozolomide
163
Radiosurgery
129
Radiotherapy
107
Bevacizumab
98
Magnetic Resonance Spectroscopy
75
Carboplatin
48
Surgical Procedures, Operative
35
pembrolizumab
34
Radiation
34
Etoposide
34
Nivolumab
33
Irinotecan
33
Cyclophosphamide
33
Erlotinib Hydrochloride
31
Carmustine
28
Trastuzumab
25
Lomustine
25
Cisplatin
25
Ipilimumab
24
Filgrastim
23
Mental Status and Dementia Tests
21
Magnetic Resonance Imaging
21
Aminolevulinic Acid
21
Vincristine
20
Surveys and Questionnaires
19
Capecitabine
19
Topotecan
18
Specimen Handling
18
Pemetrexed
18
Radiotherapy, Intensity-Modulated
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
patritumab deruxtecan
×
Clear all
NCT05865990
2026-05-04
TUXEDO-3
MedSIR
Phase 2
Completed
63 enrolled
NCT05620914
2025-06-15
PARAMETer
Duke University
Phase 2
Withdrawn